1. Home
  2. ALT

as 06-17-2025 3:30pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Founded: 1997 Country:
United States
United States
Employees: N/A City: GAITHERSBURG
Market Cap: 472.3M IPO Year: N/A
Target Price: $21.00 AVG Volume (30 days): 3.1M
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.25 EPS Growth: N/A
52 Week Low/High: $3.55 - $11.16 Next Earning Date: 08-07-2025
Revenue: $20,000 Revenue Growth: -95.12%
Revenue Growth (this year): -89.19% Revenue Growth (next year): 1557547.90%

ALT Daily Stock ML Predictions

Share on Social Networks: